VLS-211

N/A

Report date: 2025/06/11 16:56:47

Base Information

Drug NameVLS-211

Drug Alias NameVLS-211

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionDNA intercalatorsTopoisomerase (DNA) II alpha inhibitors

TargetsDNATopoisomerase (DNA) II alpha

Therapy Area/IndicationsSarcoma, EwingPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesVelosbio Inc

China Registration ClassN/A

Develop Information

Active CompaniesVelosbio Inc

Inactive CompaniesN/A

Active IndicationsSarcoma, EwingPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A